# Applications of Modern Cell Therapies: The Latest Data in Ophthalmology

## TL;DR

Modern cell therapies are being explored for treating vision loss, with potential applications in macular degeneration, retinal dystrophies, and corneal injuries, though they remain investigational.

## Contribution

This review synthesizes current cellular strategies in ophthalmology, comparing therapeutic approaches and highlighting translational challenges and future directions.

## Key findings

- Cell-based therapies show promise for retinal and corneal diseases but face challenges like tumorigenicity and immune rejection.
- Emerging approaches include allogeneic cell products, iPSC-derived grafts, and extracellular vesicles.
- Standardized outcome measures and scalable manufacturing are critical for advancing cell therapies toward clinical adoption.

## Abstract

Cell-based therapeutics are redefining interventions for vision loss by enabling tissue replacement, regeneration, and neuroprotection. This review surveys contemporary cellular strategies in ophthalmology through the lenses of therapeutic effectiveness, translational readiness, and governance. We profile principal sources—embryonic and induced pluripotent stem cells, mesenchymal stromal cells, retinal pigment epithelium, retinal progenitor and limbal stem cells—and enabling platforms including extracellular vesicles, encapsulated cell technology and biomaterial scaffolds. We synthesize clinical evidence across age-related macular degeneration, inherited retinal dystrophies, and corneal injury/limbal stem-cell deficiency, and highlight emerging applications for glaucoma and diabetic retinopathy. Delivery routes (subretinal, intravitreal, anterior segment) and graft formats (single cells, sheets/patches, organoids) are compared using standardized structural and functional endpoints. Persistent barriers include GMP-compliant derivation and release testing; differentiation fidelity, maturation, and potency; genomic stability and tumorigenicity risk; graft survival, synaptic integration, and immune rejection despite ocular immune privilege; the scarcity of validated biomarkers and harmonized outcome measures and ethical, regulatory, and health-economic constraints. Promising trajectories span off-the-shelf allogeneic products, patient-specific iPSC-derived grafts, organoid and 3D-bioprinted tissues, gene-plus-cell combinations, and cell-free extracellular-vesicle therapeutics. Overall, cell-based therapies remain investigational. With adequately powered trials, methodological harmonization, long-term surveillance, scalable xeno-free manufacturing, and equitable access frameworks, they may eventually become standards of care; at present, approvals are limited to specific products/indications and regions, and no cell therapy is the standard of care for retinal disease.